Phase III Results Put Novel Asthma Biologic on Target for Approval

(MedPage Today) -- A first-in-class drug under development for severe asthma passed what its developers hope is the final test: achieving its primary endpoint in a phase III registration trial dubbed NAVIGATOR and now reported in a major journal...